MedCity News April 18, 2024
Arundhati Parmar

A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?

Back in January, I was invited to a J.P. Morgan reception hosted by 23andMe, the storied gene testing company that Anne Wojcicki runs as co-founder and CEO.

Standing on the topmost floor of the Salesforce tower with 360-degree views of the city below — far from the tents and the grime of the downtown sidewalks — I was struck by how sparkling San Francisco is on a clear, fogless night. I wordlessly thanked whoever put me on the invitee list affording me the chance to savor...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine

Share This Article